Pathogenica Bets on Next-Gen Sequencing for Fast, Multiplexed Pathogen Detection
July 06, 2010
Pathogenica Bets on Next-Gen Sequencing for Fast, Multiplexed Pathogen Detection
The company, which is still exploring various next-gen sequencing platforms, plans to deploy its assay panels next year in a CLIA-certified lab setting and start testing them in clinical trials. It wants to launch an FDA-approved product by the end of 2012.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- NHGRI Awards More than $50M for Low-Cost DNA Sequencing Tech Development
October 13, 2009 / In Sequence - Sanger Institute's Performance Comparison of PGM, MiSeq, PacBio RS Highlights Key Differences
July 31, 2012 / In Sequence - Pathogenica Plans 2012 Launch for Sequencing-Based HPV Dx; HIV and HCV Tests in Pipeline
August 17, 2011 / Clinical Sequencing News - Ion Torrent Sales Contribute $13M to Life Tech's Q2 Top Line; Delays Hamper 5500 Revenue
August 2, 2011 / In Sequence - Papers of Note
July 26, 2011 / In Sequence